Company patents
NCAN Genomics, Inc.
NCAN Genomics, Inc. is entirely focused on Genetic & Microbiological Assays, representing 100.0% of its 36-patent portfolio. While this core area saw explosive growth in 2024 (+1200.0% YoY) and continued expansion in 2025 (+23.1% YoY), the 6 patents so far in 2026 suggest a potential shift or slowdown compared to prior full years.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
36 US filings (since 2023) · 1 categories · 4 themes
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Methods and kits for amplifying nucleic acids at a constant temperature, enabling faster results and point-of-care applications, often used for pathogen or contamination detection.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Patents
Showing 1-10 of 40